 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning Aeras Global TB Vaccine Foundation
|
-
Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
(11 Apr 2008)
Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) presented a progress update and immunology data from a Phase I Ad35 tuberculosis vaccine study at the biennial "Tuberculosis Vaccines ...
-
Vaccine formulated with Intercells adjuvant IC31 part of a broader collaboration to fight Tuberculosis
(18 Feb 2008)
Intercell AG announced that a Tuberculosis vaccine, which is currently tested in clinical trials and which contains antigens discovered by Statens Serum Institut formulated with Intercells adjuvant IC31®, will be further developed in a partnership ...
-
Statens Serum Institut, Intercell, and Aeras announce the initiation of a clinical trial for a novel TB vaccine candidate
(06 Dec 2007)
SSI's novel tuberculosis subunit vaccine HyVac4IC31 (AERAS404) enters phase I clinical trial in BCGvaccinated individuals
Statens Serum Institut (SSI), Intercell, and Aeras announced that SSI's novel prophylactic vaccine HyVac4IC31 (AERAS404) against TB have entered phase I clinical trials in BCGvaccinated individuals. The clinical trial has been initiated at the ...
-
Crucell, AERAS and SATVI Announce Start of Tuberculosis Vaccine Clinical Trial in South Africa
(15 May 2007)
Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) at the University of Cape Town announced the launch of a new Phase I clinical trial of the unique AdVac®-based tuberculosis vaccine, ...
-
Aeras commits further USD$5 million to existing TB research agreement with Crucell
(09 Mar 2007)
Crucell N.V. announced it will receive up to USD$5 million from Rockville, Maryland-headquartered Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine."This technology, which is ...
-
Crucell and AERAS Announce Start of Tuberculosis Vaccine Clinical Trial
(27 Oct 2006)
Crucell N.V. announced that it has started the phase I clinical trial of the AdVac®-based tuberculosis vaccine it is developing in partnership with The AERAS Global TB Vaccine Foundation. The clinical trial will be an open-label study that will test ...
-
ACE Biosciences and Aeras Global TB Vaccine Foundation enter tubercolosis vaccine collaboration
(22 Dec 2005)
ACE BioSciences A/S and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, US, have entered a collaboration whereby ACE BioSciences will support characterization of second-generation BCGbased tuberculosis (TB) vaccines under development ...
-
Crucell and Aeras Announce Progress in TB Vaccine Program
(12 Sep 2005)
Crucell N.V. and Aeras Global TB Vaccine Foundation announced the initiation of a series of clinical studies for their AdVac®-based TB vaccine. The studies, which follow promising results for the vaccine obtained in animal studies, are scheduled to ...
-
Aeras Receives CDC Funding to Develop TB Vaccine Trial Sites in India
(20 Sep 2004)
3 year, $2.7 Million Award to Prepare for Testing New TB Vaccines
Aeras Global TB Vaccine Foundation today announced a $925,000 cooperative agreement from the US Centers for Disease Control and Prevention to conduct epidemiologic studies in preparation for clinical trials of new tuberculosis (TB) vaccines in ...
|
|
|
|
|
Top